RU2326691C2 - Использование уреазы для ингибирования роста раковых клеток - Google Patents

Использование уреазы для ингибирования роста раковых клеток Download PDF

Info

Publication number
RU2326691C2
RU2326691C2 RU2005104113/15A RU2005104113A RU2326691C2 RU 2326691 C2 RU2326691 C2 RU 2326691C2 RU 2005104113/15 A RU2005104113/15 A RU 2005104113/15A RU 2005104113 A RU2005104113 A RU 2005104113A RU 2326691 C2 RU2326691 C2 RU 2326691C2
Authority
RU
Russia
Prior art keywords
urease
tumor
composition according
enzyme
antitumor
Prior art date
Application number
RU2005104113/15A
Other languages
English (en)
Other versions
RU2005104113A (ru
Inventor
Герман ЧАО (CA)
Герман ЧАО
Вах ВОНГ (CA)
Вах Вонг
Дональд СЕГАЛ (CA)
Дональд Сегал
Джерри МАКЭЛРОЙ (CA)
Джерри МАКЭЛРОЙ
Джон ДОЧЕРТИ (CA)
Джон Дочерти
Джоди ДИКСТЕЙН (CA)
Джоди Дикстейн
Original Assignee
Хеликс Биофарма Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хеликс Биофарма Корп. filed Critical Хеликс Биофарма Корп.
Publication of RU2005104113A publication Critical patent/RU2005104113A/ru
Application granted granted Critical
Publication of RU2326691C2 publication Critical patent/RU2326691C2/ru

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение относится к медицине и фармакологии и может быть использовано для лечения и диагностики опухолей. Настоящая композиция включает фермент уреазу и нацеливающий фрагмент, непосредственно конъюгированный с уреазой, и опционально слабоосновное противоопухолевое соединение. Изобретение обеспечивает улучшенную доставку фермента к опухолевым клеткам при введении композиции субъекту 2 н. и 4 з.п. ф-лы, 3 табл., 5 ил.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095

Claims (6)

1. Фармацевтическая композиция, предназначенная для использования при ингибировании роста опухолевых клеток у млекопитающего-субъекта, включающая фермент уреазу, нацеливающий фрагмент, непосредственно конъюгированный с указанным ферментом уреазой, выбранный из группы, состоящей из антитела к противоопухолевому антигену, антитела к анти-hCG и лиганда, способного к специфическому связыванию с поверхностными рецепторами опухолевых клеток, причем указанный нацеливающий фрагмент способен эффективно усиливать доставку фермента к опухолевым клеткам при введении композиции субъекту и опционально, слабоосновное противоопухолевое соединение, эффективность которого снижается в градиенте более высокого внутриклеточного/более низкого внеклеточного значений рН в солидной опухоли.
2. Композиция по п.1, включающая гибридный белок, состоящий из нацеливающего фрагмента и фермента уреазы.
3. Композиция по п.1, в которой указанная уреаза представляет собой растительную или бактериальную уреазу.
4. Композиция по п.1, в которой противоопухолевое соединение выбирают из группы, состоящей из доксорубицина, даунорубицина, митоксантрона, эпирубицина, митомицина, блеомицина, алкалоидов барвинка (Vinca), таких как винбластин и винкристин, алкилирующих агентов, таких как циклофосфамид и мехлорэтамина гидрохлорид, и противоопухолевых производных пурина и пиримидина.
5. Использование композиции по п.1 в производстве лекарственного средства для лечения или диагностики опухоли у млекопитающего-субъекта.
6. Использование по п.5, в котором противоопухолевое соединение выбирают из группы, состоящей из доксорубицина, даунорубицина, митоксантрона, эпирубицина, митомицина, блеомицина, алкалоидов барвинка (Vinca), таких как винбластин и винкристин, алкилирующих агентов, таких как циклофосфамид и мехлорэтамина гидрохлорид, и противоопухолевых производных пурина и пиримидина.
RU2005104113/15A 2002-07-18 2003-07-16 Использование уреазы для ингибирования роста раковых клеток RU2326691C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39724402P 2002-07-18 2002-07-18
US60/397,244 2002-07-18

Publications (2)

Publication Number Publication Date
RU2005104113A RU2005104113A (ru) 2005-09-10
RU2326691C2 true RU2326691C2 (ru) 2008-06-20

Family

ID=30771022

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005104113/15A RU2326691C2 (ru) 2002-07-18 2003-07-16 Использование уреазы для ингибирования роста раковых клеток

Country Status (23)

Country Link
US (1) US7211250B2 (ru)
EP (2) EP2324846B1 (ru)
JP (4) JP2006501196A (ru)
KR (2) KR20050038005A (ru)
CN (1) CN100577203C (ru)
AU (1) AU2003250658B2 (ru)
BR (1) BR0312664A (ru)
CA (1) CA2492472C (ru)
DK (1) DK1530482T3 (ru)
ES (1) ES2443416T3 (ru)
HK (2) HK1076739A1 (ru)
IL (1) IL166249A (ru)
MX (1) MXPA05000778A (ru)
NO (1) NO336811B1 (ru)
NZ (1) NZ538284A (ru)
PL (1) PL217626B1 (ru)
PT (1) PT1530482E (ru)
RU (1) RU2326691C2 (ru)
SI (1) SI1530482T1 (ru)
TR (1) TR200500108T2 (ru)
UA (1) UA81634C2 (ru)
WO (1) WO2004009112A1 (ru)
ZA (1) ZA200500423B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
WO2004023981A2 (en) * 2002-09-11 2004-03-25 Duke University Methods and compositions for blood pool identification, drug distribution quantification and drug release verification
US7769423B2 (en) * 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20070104732A1 (en) * 2003-10-24 2007-05-10 Bernard Massie Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
EP2984170A4 (en) * 2013-04-08 2016-11-30 Helix Biopharma Corp USE OF ANTIBODY UREASE CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
KR102318994B1 (ko) * 2015-01-23 2021-10-29 헬릭스 바이오파마 코포레이션 치료학적 목적을 위한 항체-우레아제 접합체
CN110022891A (zh) 2016-09-24 2019-07-16 赫利克斯生物药品公司 恢复肿瘤酸化t细胞的功能
CN110382551A (zh) * 2017-01-05 2019-10-25 赫利克斯生物药品公司 抗vegfr-2脲酶缀合物
WO2021235436A1 (ja) * 2020-05-20 2021-11-25 株式会社メドレックス アポモルヒネ含有経皮吸収型製剤
MX2022015897A (es) * 2020-06-15 2023-01-24 Kortuc Inc Sensibilizador para el tratamiento del cancer.
CN113433087A (zh) * 2021-06-22 2021-09-24 中南大学 一种尿素浓度快速检测方法及检测传感器和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329332A (en) 1978-07-19 1982-05-11 Patrick Couvreur Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them
US4489055A (en) 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2504408B1 (fr) 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4824783A (en) 1983-12-20 1989-04-25 Enichem S.P.A. Oxidized sulfur derivatives of diaminophosphinyl compounds as urease inhibitors
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4837380A (en) * 1985-09-30 1989-06-06 Regents Of University Of California Liposome-calcitonin preparation
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4680333A (en) 1986-04-14 1987-07-14 National Starch And Chemical Corporation Removable hot melt pressure sensitive adhesive
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
FR2637612B1 (fr) 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
US5298399A (en) 1990-08-10 1994-03-29 Sapporo Breweries Limited Gene and process for producing a thermostable urease
US5140100A (en) 1990-12-28 1992-08-18 Cedars-Sinai Medical Center Protein that inhibits production of human choriogonadotropin
FR2683159B1 (fr) 1991-10-31 1994-02-25 Coletica Procede de fabrication de nanocapsules a paroi a base de proteines reticulees; nanocapsules ainsi obtenues et compositions cosmetiques, pharmaceutiques et alimentaires en comportant application.
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
AU3940293A (en) * 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
GB9300875D0 (en) 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
CA2151742C (en) 1993-02-22 1999-05-25 Alfred A. Amkraut Compositions for oral delivery of active agents
JPH08509873A (ja) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
WO1995031480A1 (en) * 1994-05-18 1995-11-23 S.P.I. Synthetic Peptides Incorporated Heterodimer polypeptide immunogen carrier composition and method
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US5886143A (en) 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
JPH11511979A (ja) * 1995-09-06 1999-10-19 ババリアン・ノルディック・リサーチ・インスティテュート・アクティーゼルスカブ ヒト乳癌細胞を含むヒト乳腺細胞を標的として、連結された異種性遺伝子を発現させるためのｗａｐまたはｍｍｔｖ制御配列の使用
US6149904A (en) 1996-01-31 2000-11-21 The Regents Of The University Of California Method for inhibiting tumor cell growth by administering to tumor cells expressing a nucleic acid encoding a connexin and a pro-drug
CA2250222A1 (en) 1996-03-20 1997-09-25 Mien-Chie Hung Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
JPH1017492A (ja) * 1996-07-02 1998-01-20 Fuji Yakuhin Kogyo Kk 腫瘍細胞増殖抑制剤
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5750496A (en) * 1996-08-12 1998-05-12 Utah State University Method of controlling cryptosporidium infectons using protease inhibitors
EP0824019B1 (en) * 1996-08-13 2002-11-20 Quest International B.V. Inhibition or reduction of oral malodour
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
US6180114B1 (en) 1996-11-21 2001-01-30 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
GB9703633D0 (en) 1997-02-21 1997-04-09 Imp Cancer Res Tech Cancer therapy
US6190923B1 (en) 1997-09-05 2001-02-20 David K. Johnson Diethylenetriamine-N,N′,N″-triacetic acid derivatives
FR2772025B1 (fr) 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
EP1122262B1 (en) * 1998-10-16 2009-12-30 Otsuka Pharmaceutical Co., Ltd. Neovascular-specific peptides
FR2790405B1 (fr) 1999-03-02 2001-04-20 Oreal Nanocapsules a base de polymeres dendritiques
US6300141B1 (en) 1999-03-02 2001-10-09 Helix Biopharma Corporation Card-based biosensor device
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
CH694589A5 (de) 1999-06-25 2005-04-15 Genentech Inc Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern.
US6307372B1 (en) 1999-11-02 2001-10-23 Glaxo Wellcome, Inc. Methods for high throughput chemical screening using magnetic resonance imaging
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
WO2002015925A1 (fr) * 2000-08-22 2002-02-28 Kyowa Hakko Kogyo Co., Ltd. Technique de regulation de l'apoptose et polypeptide de regulation d'apoptose
US7148038B2 (en) * 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shi G et. al "Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations.", J Control Release, 2002 Apr. 23; 80(1-3):309-19. Bagshawe KD et. al "A cytotoxic agent can be generated selectively at cancer sites.", Br. J Cancer, 1988 Dec; 58(6):700-3. *

Also Published As

Publication number Publication date
EP2324846B1 (en) 2014-11-12
AU2003250658A1 (en) 2004-02-09
US7211250B2 (en) 2007-05-01
KR20050038005A (ko) 2005-04-25
EP2324846A1 (en) 2011-05-25
HK1158103A1 (en) 2012-07-13
IL166249A (en) 2011-10-31
NZ538284A (en) 2008-04-30
KR20110123786A (ko) 2011-11-15
JP2011207913A (ja) 2011-10-20
BR0312664A (pt) 2005-05-03
EP1530482B9 (en) 2014-04-16
CA2492472A1 (en) 2004-01-29
EP1530482B1 (en) 2013-10-23
WO2004009112A8 (en) 2005-09-15
SI1530482T1 (sl) 2014-03-31
PL374675A1 (en) 2005-10-31
ES2443416T3 (es) 2014-02-19
RU2005104113A (ru) 2005-09-10
NO336811B1 (no) 2015-11-02
PL217626B1 (pl) 2014-08-29
IL166249A0 (en) 2006-01-15
TR200500108T2 (tr) 2005-04-21
NO20050793L (no) 2005-04-18
JP2006501196A (ja) 2006-01-12
MXPA05000778A (es) 2005-08-29
PT1530482E (pt) 2014-01-15
EP1530482A1 (en) 2005-05-18
HK1076739A1 (en) 2006-01-27
KR101352826B1 (ko) 2014-01-17
DK1530482T3 (da) 2014-01-20
JP2013213055A (ja) 2013-10-17
JP5850561B2 (ja) 2016-02-03
JP2016014066A (ja) 2016-01-28
WO2004009112A1 (en) 2004-01-29
ZA200500423B (en) 2006-08-30
CN100577203C (zh) 2010-01-06
US20040115186A1 (en) 2004-06-17
AU2003250658B2 (en) 2009-07-16
CA2492472C (en) 2014-01-07
UA81634C2 (ru) 2008-01-25
CN1681528A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
RU2326691C2 (ru) Использование уреазы для ингибирования роста раковых клеток
JP2013213055A5 (ru)
US10092659B2 (en) Duocarmycin ADCs for use in treatment of endometrial cancer
US20190314513A1 (en) Duocarmycin adcs showing improved in vivo antitumor activity
JP7286179B2 (ja) Ａｘｌデコイ受容体を用いる転移性癌の治療方法
JP2013231065A (ja) 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用
KR20210093250A (ko) 재조합 단백질과의 조합 화학요법
US8552014B2 (en) Methods of using selective chemotherapeutic agents for targeting tumor cells
WO2007117419A2 (en) Methods and compositions relating to post-prolyl cleaving enzyme inhibitors
WO2005025623A3 (en) Ef-24-factor vii conjugates
US7981902B2 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with FR type receptors
US20080090752A1 (en) Anti-tumor vasculature effects of human serum albumin derivatives
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
CN117813115A (zh) 用于癌症的分子成像和免疫治疗的δ-阿片受体靶向试剂
KR20230050349A (ko) Axl 유인 수용체를 이용한 암의 진단 방법
CN116930494A (zh) Icam1或其编码基因在制备宫颈癌治疗或诊断产品中的用途
Powis Cancer chemotherapy II: laboratory to clinic
Dudás et al. New drugs for head and neck cancer
Zhang et al. Inhibition of human lung adenocarcinoma cells by 5F11-doxorubicin immunoconjugate in vitro and in vivo
Watt Functional interactions between epidermal growth factor receptors and somatostatin receptors: A novel strategy for therapeutic interventions against solid tumours